US FDA extends review of Capricor's muscle disorder therapy by three months
CAPR•FDA extends review period for Capricor therapy
Aug. 24 (Reuters) - Capricor Therapeutics said on Monday that the U.S. Food and Drug Administration had extended the review of its experimental cell therapy for Duchenne muscular dystrophy by three months.
